Journal of Antimicrobial Chemotherapy (2003) 51, ii9-ii16
© 2003 The British Society for Antimicrobial Chemotherapy
Supplement |
Linezolid in vitro: mechanism and antibacterial spectrum
Antibiotic Resistance Monitoring and Reference Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
Abstract
Oxazolidinones are prominent among the new Gram-positive antimicrobial agents now becoming available. They were discovered by DuPont Pharmaceuticals in the late 1980s but linezolid, the first analogue suitable for development, was found only when the family was re-examined by Pharmacia in the 1990s. Oxazolidinones bind to the 50S subunit of the prokaryotic ribosome, preventing formation of the initiation complex for protein synthesis. This is a novel mode of action; other protein synthesis inhibitors either block polypeptide extension or cause misreading of mRNA. Linezolid MICs vary slightly with the test method, laboratory, and significance attributed to thin hazes of bacterial survival, but all workers find that the susceptibility distributions are narrow and unimodal, with MIC values between 0.5 and 4 mg/L for streptococci, enterococci and staphylococci. Full activity is retained against Gram-positive cocci resistant to other antibiotics, including methicillin-resistant staphylococci and vancomycin-resistant enterococci. MICs are 4–8 mg/L for Moraxella, Pasteurella and Bacteroides spp. but other Gram-negative bacteria are resistant as a result of endogenous efflux activity. Resistance is difficult to select in vitro but has been reported during therapy in a few enterococcal infections and in two MRSA cases to date; the mechanism entails mutation of the 23S rRNA that forms the binding site for linezolid. Risk factors for selection of resistance include indwelling devices, undrained foci, protracted therapy and underdosage.
Footnotes
* Tel: +44-20-8200-4400; Fax: +44-20-8358-3292; E-mail: dlivermore{at}hpa.org.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Paul-Satyaseela, S. S. Solanki, D. Sathishkumar, T. Bharani, V. Magesh, and S. Rajagopal In vitro antibacterial activities of a novel oxazolidinone, OCID0050 J. Antimicrob. Chemother., October 1, 2009; 64(4): 797 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Murillo, C. Garrigos, M. E. Pachon, G. Euba, R. Verdaguer, C. Cabellos, J. Cabo, F. Gudiol, and J. Ariza Efficacy of High Doses of Daptomycin versus Alternative Therapies against Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4252 - 4257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, S. Mushtaq, M. Warner, and N. Woodford Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci J. Antimicrob. Chemother., April 1, 2009; 63(4): 713 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore Future directions with daptomycin J. Antimicrob. Chemother., November 1, 2008; 62(suppl_3): iii41 - iii49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Besier, A. Ludwig, J. Zander, V. Brade, and T. A. Wichelhaus Linezolid Resistance in Staphylococcus aureus: Gene Dosage Effect, Stability, Fitness Costs, and Cross-Resistances Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1570 - 1572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Tenover, P. P. Williams, S. Stocker, A. Thompson, L. A. Clark, B. Limbago, R. B. Carey, S. M. Poppe, D. Shinabarger, and J. E. McGowan Jr. Accuracy of Six Antimicrobial Susceptibility Methods for Testing Linezolid against Staphylococci and Enterococci J. Clin. Microbiol., September 1, 2007; 45(9): 2917 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Soriano, M. Ortega, S. Garcia, G. Penarroja, A. Bove, M. Marcos, J. C. Martinez, J. A. Martinez, and J. Mensa Comparative Study of the Effects of Pyridoxine, Rifampin, and Renal Function on Hematological Adverse Events Induced by Linezolid Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2559 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schumacher, R. Trittler, J. A. Bohnert, K. Kummerer, J.-M. Pages, and W. V. Kern Intracellular accumulation of linezolid in Escherichia coli, Citrobacter freundii and Enterobacter aerogenes: role of enhanced efflux pump activity and inactivation J. Antimicrob. Chemother., June 1, 2007; 59(6): 1261 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garrabou, A. Soriano, S. Lopez, J. P. Guallar, M. Giralt, F. Villarroya, J. A. Martinez, J. Casademont, F. Cardellach, J. Mensa, et al. Reversible Inhibition of Mitochondrial Protein Synthesis during Linezolid-Related Hyperlactatemia Antimicrob. Agents Chemother., March 1, 2007; 51(3): 962 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Livermore, M. Warner, S. Mushtaq, S. North, and N. Woodford In Vitro Activity of the Oxazolidinone RWJ-416457 against Linezolid-Resistant and -Susceptible Staphylococci and Enterococci Antimicrob. Agents Chemother., March 1, 2007; 51(3): 1112 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Foleno, D. Abbanat, R. M. Goldschmidt, R. K. Flamm, S. D. Paget, G. C. Webb, E. Wira, M. J. Macielag, and K. Bush In Vitro Antibacterial Activity of the Pyrrolopyrazolyl-Substituted Oxazolidinone RWJ-416457 Antimicrob. Agents Chemother., January 1, 2007; 51(1): 361 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Draghi, D. J. Sheehan, P. Hogan, and D. F. Sahm In Vitro Activity of Linezolid against Key Gram-Positive Organisms Isolated in the United States: Results of the LEADER 2004 Surveillance Program Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5024 - 5032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Soriano, O. Miro, and J. Mensa Mitochondrial Toxicity Associated with Linezolid. N. Engl. J. Med., November 24, 2005; 353(21): 2305 - 2306. [Full Text] [PDF]
|
|
|
|
|
|
H. Carsenti-Dellamonica, M. Galimand, F. Vandenbos, C. Pradier, P. M. Roger, B. Dunais, M. Sabah, G. Mancini, and P. Dellamonica In vitro selection of mutants of Streptococcus pneumoniae resistant to macrolides and linezolid: relationship with susceptibility to penicillin G or macrolides J. Antimicrob. Chemother., October 1, 2005; 56(4): 633 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kosowska, D. B. Hoellman, G. Lin, C. Clark, K. Credito, P. McGhee, B. Dewasse, B. Bozdogan, S. Shapiro, and P. C. Appelbaum Antipneumococcal Activity of Ceftobiprole, a Novel Broad-Spectrum Cephalosporin Antimicrob. Agents Chemother., May 1, 2005; 49(5): 1932 - 1942. [Abstract] [Full Text] [PDF]
|
|